









市場行情
/
股票
/
nasdaq-krro
/

Korro Bio Inc

KRRO

8.120USD

-0.290-3.45%

收盤 12/26, 16:00（美東）報價延遲15分鐘

76.31M總市值

虧損本益比TTM



Korro Bio Inc

8.120

-0.290-3.45%

概覽公司財務分析

概覽

公司

財務

分析

關於 Korro Bio Inc 公司

Korro Bio, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.

Korro Bio Inc簡介



公司代碼KRRO

公司名稱Korro Bio Inc

上市日期Oct 03, 2019

CEODr. Ram Aiyar, Ph.D.

員工數量104

證券類型Ordinary Share

年結日Oct 03

公司地址One Kendall Square. Building 600-700

城市CAMBRIDGE

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編02139

電話16174681999

網址https://www.korrobio.com/

公司代碼KRRO

上市日期Oct 03, 2019

CEODr. Ram Aiyar, Ph.D.

Korro Bio Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Nessan Bermingham, Ph.D.

Independent Chairman of the Board

35.11K

Mr. Jeffrey (Jeff) Cerio, Pharm.D.

Senior Vice President, General Counsel, Corporate Secretary

Mr. Oliver Dolan

Principal Accounting Officer

Dr. Ali Behbahani, M.D.

Independent Director

Mr. Venkat Krishnamurthy, Ph.D.

Senior Vice President - Platform

Ms. Stephanie Engels

Senior Vice President - People and Culture

Dr. Rachel Meyers, Ph.D.

Independent Director

Dr. Katharine (Kate) Knobil, M.D.

Independent Director

Mr. Todd Chappell

Chief Operating Officer

Dr. Ram Aiyar, Ph.D.

President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director

名稱

名稱/職務

職務

持股

持股變動

Dr. Nessan Bermingham, Ph.D.

Independent Chairman of the Board

35.11K

Mr. Jeffrey (Jeff) Cerio, Pharm.D.

Senior Vice President, General Counsel, Corporate Secretary

Mr. Oliver Dolan

Principal Accounting Officer

Dr. Ali Behbahani, M.D.

Independent Director

Mr. Venkat Krishnamurthy, Ph.D.

Senior Vice President - Platform

Ms. Stephanie Engels

Senior Vice President - People and Culture

收入明細

FY2025Q2

FY2025Q1

FY2024

由於公司未披露，未能獲取相關數據

地區USD

名稱

營收

佔比

United States

1.46M

0.00%

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 12月5日週五

持股股東

股東類型

持股股東

佔比

Atlas Venture

12.08%

New Enterprise Associates (NEA)

11.58%

Driehaus Capital Management, LLC

7.14%

Fidelity Management & Research Company LLC

5.99%

Platanus Investment LLC

5.74%

其他

57.48%

持股股東

佔比

Atlas Venture

12.08%

New Enterprise Associates (NEA)

11.58%

Driehaus Capital Management, LLC

7.14%

Fidelity Management & Research Company LLC

5.99%

Platanus Investment LLC

5.74%

其他

57.48%

股東類型

持股股東

佔比

Investment Advisor

37.54%

Venture Capital

24.12%

Hedge Fund

23.55%

Investment Advisor/Hedge Fund

16.05%

Corporation

5.74%

Research Firm

2.19%

Individual Investor

1.54%

Private Equity

0.34%

Bank and Trust

0.27%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

186

9.33M

99.33%

-1.07M

2025Q2

186

10.38M

110.55%

-200.85K

2025Q1

189

10.53M

112.24%

-76.97K

2024Q4

194

10.26M

109.50%

+485.90K

2024Q3

177

9.16M

98.29%

-245.98K

2024Q2

167

9.06M

97.57%

+507.87K

2024Q1

179

7.52M

93.89%

+737.20K

2023Q4

198

7.18M

91.01%

+1.51M

2023Q3

223

264.10K

35.84%

-47.15K

2023Q2

235

150.53K

21.10%

-156.09K

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Atlas Venture

1.14M

12.11%

Jun 30, 2025

New Enterprise Associates (NEA)

1.09M

11.62%

Jun 30, 2025

Driehaus Capital Management, LLC

580.86K

6.19%

-1.59K

-0.27%

Jun 30, 2025

Fidelity Management & Research Company LLC

639.22K

6.81%

-4.05K

-0.63%

Jun 30, 2025

Platanus Investment LLC

540.16K

5.75%

Apr 15, 2025

Point72 Asset Management, L.P.

540.07K

5.75%

+19.18K

+3.68%

Jun 30, 2025

Cormorant Asset Management, LP

465.00K

4.95%

+84.70K

+22.27%

Jun 30, 2025

Invus Public Equities Advisors, LLC

418.83K

4.46%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

423.16K

4.51%

+15.35K

+3.76%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

iShares Micro-Cap ETF

0.05%

Avantis US Small Cap Equity ETF

0.02%

Global X Russell 2000 ETF

0.01%

Proshares Ultra Russell 2000

0.01%

ProShares UltraPro Russell2000

SPDR Portfolio MSCI Global Stock Market ETF

ProShares Hedge Replication ETF

Invesco Dorsey Wright SmallCap Momentum ETF

iShares Russell 2000 Growth ETF

iShares Russell 3000 ETF

iShares Micro-Cap ETF

佔比0.05%

Avantis US Small Cap Equity ETF

佔比0.02%

Global X Russell 2000 ETF

佔比0.01%

Proshares Ultra Russell 2000

佔比0.01%

ProShares UltraPro Russell2000

佔比0%

SPDR Portfolio MSCI Global Stock Market ETF

佔比0%

ProShares Hedge Replication ETF

佔比0%

Invesco Dorsey Wright SmallCap Momentum ETF

佔比0%

iShares Russell 2000 Growth ETF

佔比0%

iShares Russell 3000 ETF

佔比0%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

Nov 03, 2023

Merger

50→1

Nov 03, 2023

Merger

50→1

Nov 03, 2023

Merger

50→1

Nov 03, 2023

Merger

50→1

公告日期

類型

比率

Nov 03, 2023

Merger

50→1

Nov 03, 2023

Merger

50→1

Nov 03, 2023

Merger

50→1

Nov 03, 2023

Merger

50→1

常見問題

Korro Bio Inc的前五大股東是誰？



Korro Bio Inc的前五大股東如下：
Atlas Venture
持有股份：1.14M
佔總股份比例：12.11%。
New Enterprise Associates (NEA)
持有股份：1.09M
佔總股份比例：11.62%。
Driehaus Capital Management, LLC
持有股份：580.86K
佔總股份比例：6.19%。
Fidelity Management & Research Company LLC
持有股份：639.22K
佔總股份比例：6.81%。
Platanus Investment LLC
持有股份：540.16K
佔總股份比例：5.75%。